Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome
- 24 August 2015
- journal article
- research article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2015 (8), CD000144
- https://doi.org/10.1002/14651858.cd000144.pub3
Abstract
A wide variety of surfactant preparations have been developed and tested including synthetic surfactants and surfactants derived from animal sources. Although clinical trials have demonstrated that both synthetic surfactant and animal derived surfactant preparations are effective, comparison in animal models has suggested that there may be greater efficacy of animal derived surfactant products, perhaps due to the protein content of animal derived surfactant. To compare the effect of animal derived surfactant to protein free synthetic surfactant preparations in preterm infants at risk for or having respiratory distress syndrome (RDS). Searches were updated of the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2014), PubMed, CINAHL and EMBASE (1975 through November 2014). All languages were included. Randomized controlled trials comparing administration of protein free synthetic surfactants to administration of animal derived surfactant extracts in preterm infants at risk for or having respiratory distress syndrome were considered for this review. Data collection and analysis were conducted according to the standards of the Cochrane Neonatal Review Group. Fifteen trials met the inclusion criteria. The meta‐analysis showed that the use of animal derived surfactant rather than protein free synthetic surfactant resulted in a significant reduction in the risk of pneumothorax [typical relative risk (RR) 0.65, 95% CI 0.55 to 0.77; typical risk difference (RD) ‐0.04, 95% CI ‐0.06 to ‐0.02; number needed to treat to benefit (NNTB) 25; 11 studies, 5356 infants] and a marginal reduction in the risk of mortality (typical RR 0.89, 95% CI 0.79 to 0.99; typical RD ‐0.02, 95% CI ‐0.04 to ‐0.00; NNTB 50; 13 studies, 5413 infants). Animal derived surfactant was associated with an increase in the risk of necrotizing enterocolitis [typical RR 1.38, 95% CI 1.08 to 1.76; typical RD 0.02, 95% CI 0.01 to 0.04; number needed to treat to harm (NNTH) 50; 8 studies, 3462 infants] and a marginal increase in the risk of any intraventricular hemorrhage (typical RR 1.07, 95% CI 0.99 to 1.15; typical RD 0.02, 95% CI 0.00 to 0.05; 10 studies, 5045 infants) but no increase in Grade 3 to 4 intraventricular hemorrhage (typical RR 1.08, 95% CI 0.91 to 1.27; typical RD 0.01, 95% CI ‐0.01 to 0.03; 9 studies, 4241 infants). The meta‐analyses supported a marginal decrease in the risk of bronchopulmonary dysplasia or mortality associated with the use of animal derived surfactant preparations (typical RR 0.95, 95% CI 0.91 to 1.00; typical RD ‐0.03, 95% CI ‐0.06 to 0.00; 6 studies, 3811 infants). No other relevant differences in outcomes were noted. Both animal derived surfactant extracts and protein free synthetic surfactant extracts are effective in the treatment and prevention of respiratory distress syndrome. Comparative trials demonstrate greater early improvement in the requirement for ventilator support, fewer pneumothoraces, and fewer deaths associated with animal derived surfactant extract treatment. Animal derived surfactant may be associated with an increase in necrotizing enterocolitis and intraventricular hemorrhage, though the more serious hemorrhages (Grade 3 and 4) are not increased. Despite these concerns, animal derived surfactant extracts would seem to be the more desirable choice when compared to currently available protein free synthetic surfactants.Keywords
This publication has 50 references indexed in Scilit:
- Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndromeCochrane Database of Systematic Reviews, 2009
- Core ConceptsNeoReviews, 2009
- Surfactant for meconium aspiration syndrome in full term/near term infantsPublished by Wiley ,2007
- New Synthetic Surfactants: The Next Generation?Neonatology, 2005
- Comparison of the changes in the a/A oxygen ratio after administration of two surfactants for the treatment of neonatal respiratory distress syndromeJournal of Tropical Pediatrics, 1997
- A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndromeThe Journal of Pediatrics, 1996
- Pulmonary mechanics in ventilated preterm infants with respiratory distress syndrome after exogenous surfactant administration: A comparison between two surfactant preparationsPediatric Pulmonology, 1994
- Deficiency of Pulmonary Surfactant Protein B in Congenital Alveolar ProteinosisNew England Journal of Medicine, 1993
- Comparison of clinical responses to natural and synthetic surfactantsjpme, 1993
- Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1,500 gmThe Journal of Pediatrics, 1978